Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab and Dasatinib in Rhabdomyosarcoma
NCT03041701Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2017
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ganitumab in alveolar rhabdomyosarcoma (ARMS), sponsored by National Cancer Institute. Started Jul 2017; status: terminated.
02
Drugs
ganitumab
03
Conditions
alveolar rhabdomyosarcoma (ARMS)
Beyond the preview
Go deeper on NCT03041701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041701.